Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Inclusion Criteria: * PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS: * Age: 50 or older, plus at least one of the following: * Mutation unknown or absent: * 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; * OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\] * Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following: * CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1) * OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of: * ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53 * HIGH-RISK OR WORRISOME PANCREATIC CYSTS: * 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria * High risk stigmata: * Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas * Enhancing mural nodule ≥ 5 mm * Main pancreatic duct ≥ 10 mm * Worrisome features: * Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm * Cyst ≥ 3 cm * Enhancing mural nodule \< 5 mm * Thickened/Enhancing cyst wall * Main duct size 5-9 mm * Pancreatitis * Lymphadenopathy * Increased CA 19-9 * Cyst growth rate ≥ 5 mm /2 years Exclusion Criteria: * Is unable to provide informed consent * Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma) * Current or prior history of PDAC or total pancreatectomy * Is currently a prison inmate * Is not able to speak or read English